Edition:
United Kingdom

China Resources Pharmaceutical Group Ltd (3320.HK)

3320.HK on Hong Kong Stock

10.92HKD
14 Dec 2018
Change (% chg)

HK$-0.34 (-3.02%)
Prev Close
HK$11.26
Open
HK$11.82
Day's High
HK$11.82
Day's Low
HK$10.84
Volume
2,952,862
Avg. Vol
3,665,258
52-wk High
HK$13.16
52-wk Low
HK$9.54

Latest Key Developments (Source: Significant Developments)

China Resources Pharmaceutical Group Posts HY Profit Attributable Of HK$2.25 Bln
Friday, 24 Aug 2018 

Aug 24 (Reuters) - China Resources Pharmaceutical Group Ltd <3320.HK>::HY PROFIT ATTRIBUTABLE HK$2.25 BILLION VERSUS HK$1.81 BILLION.HY REVENUE HK$93.74 BILLION VERSUS HK$82.74 BILLION.  Full Article

China Resources Sanjiu Medical & Pharmaceutical to pay FY 2017 annual div on June 21
Tuesday, 12 Jun 2018 

June 12(Reuters) - China Resources Sanjiu Medical & Pharmaceutical Co Ltd <000999.SZ> ::Says it plans to pay FY 2017 dividend to shareholders of record on June 20.The company's shares will be traded ex-right and ex-dividend on June 21 and the dividend will be paid on June 21.  Full Article

China Resources Pharmaceutical Group Updates On Buying Controlling Stake In Jiangzhong Group
Monday, 4 Jun 2018 

June 4 (Reuters) - China Resources Pharmaceutical Group Ltd <3320.HK>::UPDATES ON RESTRUCTURE WHEREBY CO WILL ACQUIRE CONTROLLING STAKE IN JIANGZHONG GROUP.OFFER PRICE OF FOR GENERAL OFFER FOR JIANGZHONG PHARMACEUTICAL CO SHALL BE RMB25.03 PER SHARE.TOTAL MAXIMUM CAPITAL AMOUNT NEEDED FOR OFFER IS RMB4.28 BILLION.NUMBER OF SHARES SUBJECT TO OFFER IS 170.9 MILLION LISTED TRADABLE SHARES OF JIANGZHONG PHARMACEUTICAL.COMPLETION OF PROPOSED ACQUISITION WILL TRIGGER OBLIGATION OF GENERAL OFFER FOR SHARES OF JIANGZHONG PHARMA.  Full Article

China Resources Pharmaceutical Group Says In Talks With Jiangxi Government
Wednesday, 16 May 2018 

May 16 (Reuters) - China Resources Pharmaceutical Group Ltd <3320.HK>::IN TALKS WITH JIANGXI GOVERNMENT FOR PROPOSED STRATEGIC COOPERATION FRAMEWORK DEAL.CO AND JIANGXI GOVERNMENT CONTEMPLATE TO RESTRUCTURE JIANGZHONG GROUP WHEREBY CO WILL ACQUIRE CONTROLLING STAKE.FRAMEWORK DEAL TO ESTABLISH RELATIONSHIP AIMING TO PROMOTE DEVELOPMENT OF PHARMACEUTICAL INDUSTRY IN JIANGXI.  Full Article

China Resources Pharmaceutical Group Says Unit Enters Loan Agreement With CR Leasing
Monday, 7 May 2018 

May 7 (Reuters) - China Resources Pharmaceutical Group Ltd <3320.HK>::ENTERED INTO LOAN AGREEMENT WITH CR LEASING IN RESPECT OF LOAN IN AMOUNT OF HK$3 BILLION FOR 1 YEAR.  Full Article

China Resources Double-crane Pharmaceutical unit receives GMP certificate
Wednesday, 24 Jan 2018 

Jan 24 (Reuters) - China Resources Double-crane Pharmaceutical Co Ltd <600062.SS>:Says wholly owned pharmaceutical unit received goods manufacture practice (GMP) certificate from Henan Food and Drug Administration .Certificate issued to edaravone manufactured by the unit and the valid period is until Jan. 7, 2023 .  Full Article

China Resources Pharmaceutical Announces Proposed Capital Contribution To CR Leasing
Thursday, 28 Dec 2017 

Dec 28 (Reuters) - China Resources Pharmaceutical Group Ltd <3320.HK>::UNITS, ENTERS CAPITAL CONTRIBUTION AGREEMENT WITH CR LEASING (HONG KONG) & CR LEASING.DEAL FOR PROPOSED CAPITAL CONTRIBUTION OF RMB 889.4 MILLION​.  Full Article

China Resources Pharmaceutical Group Declares Special Dividend
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - China Resources Pharmaceutical Group Ltd <3320.HK>::RESOLVED TO DECLARE SPECIAL DIVIDEND IN AMOUNT OF HK$668.3 MILLION.  Full Article

China Resources Pharmaceutical Group's units enter agreement to establish fund
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - China Resources Pharmaceutical Group Ltd <3320.HK>:Units of co enter agreement with other partners in relation to establishment of fund of RMB2,500 million​.‍Proposed aggregate capital commitment of group to fund RMB305.25 million​.  Full Article

China Resources Pharmaceutical says 9-mnth net profit RMB970.2 mln ​‍​
Monday, 30 Oct 2017 

Oct 30 (Reuters) - China Resources Pharmaceutical Group Ltd <3320.HK>:9-month net profit RMB970.2 million versus RMB878.2 million ‍a year ago​.9-mnth ‍revenue RMB7.48 billion versus RMB6.16 billion ​‍​.  Full Article

Chinese biotech firm Ascletis set to open higher in HK debut

HONG KONG, Aug 1 Shares of Chinese firm Ascletis Pharma Inc were set to open 5.7 percent above their issue price on debut in Hong Kong on Wednesday, the first such listing in the city under new rules designed to attract early-state biotechs.